Pfizer prunes three drugs from its pipeline; Astellas in-licenses ear drug
• Pfizer’s latest pipeline update comes with a notice of three midnight program executions. The pharma giant has pruned three drugs from its substantial pipeline, according to the update. The most advanced is a Phase II diabetes program for PF-06291874; followed by the early stage cardio drug PF-06815345 (hyperlipidemia) as well as the neuro drug PF-06412562, also in Phase I. None of these were high profile projects, none of the terminations were explained.
• Astellas Pharma has licensed the AU-935 program, a therapy for eardrum perforations, from Auration Biotech.
• AbCheck s.r.o. says it achieved the first clinical milestone in its antibody discovery collaboration with Eli Lilly. The milestone, triggered by the commencement of patient enrollment for a Phase I study of an antibody discovered under the collaboration agreement, provides an undisclosed milestone payment from Lilly.
• BioClinica CEO John Hubbard was elected chairman of ACRO, an advocacy group for CROs and clinical services organizations around the world.